Hizentra 200mg/ml Solution for Subcutaneous Injection
Hizentra 200mg/ml Solution for Subcutaneous Injection, Human Normal Immunoglobulin is indicated for:
Replacement therapy in adults, children and adolescents (0-18 years) in:
- Primary immunodeficiency syndromes with impaired antibody production (see section 4.4),
- Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (CLL), in whom prophylactic antibiotics have failed or are contra-indicated,
- Hypogammaglobulinaemia and recurrent infections in multiple myeloma (MM) patients,
- Hypogammaglobulinaemia in patients pre- and post-allogeneic haematopoietic stem cell transplantation (HSCT).
Hizentra is available in the following presentations:
- 1g in 5ml vial
- 2g in 10ml vial
- 4g in 20ml vial
Please visit our Privigen page for information on our Solution for Infusion, Human Normal Immunoglobulin.
Method of Sale: POM
License Number: EU/1/11/687/001, EU/1/11/687/004 & EU/1/11/687/010
MAH Holder: CSL Behring GmbH
For any further information please speak to your local Fannin Representative or for a copy of the SPC please contact our medical information department at email@example.com or via phone on 086 839 4447.
Hizentra is distributed in Ireland by Fannin Ltd. in partnership with CSL Behring. (This link will take you to a non-Fannin Ltd. website. Fannin Ltd. does not recommend, endorse or accept liability for sites controlled by third-parties.)
IE2017/058/00 Date of Preparation: October 2017
ROI orders / enquiries please contact
+353 1 2907000
+353 1 2907111
Pharma orders / enquiries please contact